Tyler F. Stewart, MD, presented “Point-Counterpoint: Cystectomy vs. Trimodal Therapy for Muscle Invasive Bladder Cancer – Trimodal Therapy” during the 30th Annual Perspectives in Urology: Point-Counterpoint, on March 10, 2023, at Humphreys Half Moon Inn, San Diego, California.
How to cite: Stewart, Tyler F. “Point-Counterpoint: Cystectomy vs. Trimodal Therapy for Muscle Invasive Bladder Cancer – Trimodal Therapy.” March 10, 2023. Accessed Nov 2024. https://grandroundsinurology.com/point-counterpoint-cystectomy-vs-trimodal-therapy-for-muscle-invasive-bladder-cancer-trimodal-therapy/
Point-Counterpoint: Cystectomy vs. Trimodal Therapy for Muscle Invasive Bladder Cancer – Trimodal Therapy – Summary
Dr. Tyler F. Stewart, MD, presents a comprehensive discussion on the topic of cystectomy versus trimodal therapy for muscle invasive bladder cancer. Highlighting the importance of a multidisciplinary approach, he emphasizes that the decision-making process involves urologists, medical oncologists, and radiation oncologists working as a team.
Dr. Stewart explores the current treatment strategies, comparing the outcomes of cystectomy and chemoradiation based on existing studies. He acknowledges the life-saving potential of cystectomies and recognizes specific scenarios where it remains the preferred option. However, he also highlights the complications associated with cystectomy, such as quality of life issues and post-surgical challenges.
Additionally, Dr. Stewart discusses trimodal therapy, which involves a combination of maximal debulking, chemoradiation, and ongoing surveillance. He addresses the lack of definitive randomized trials in this area and presents retrospective studies demonstrating comparable oncologic outcomes between trimodal therapy and cystectomy with neoadjuvant chemotherapy.
Dr. Stewart delves into the complications and late toxicities associated with trimodal therapy while discussing its potential benefits in terms of quality of life outcomes. He concludes by mentioning the exciting advancements in systemic therapies and ongoing research to improve local disease control in bladder sparing options.
This lecture is part of a Point-Counterpoint debate. Its opposing lecture is “Point-Counterpoint: Cystectomy vs. Trimodal Therapy for Muscle Invasive Bladder Cancer–Cystectomy.”
About the 30th Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.
